Schott Pharma rises after Barclays upgrades to 'overweight' on accelerating growth outlook

SCHOTT Pharma AG & Co. KGaA

18/08/2026 07:39

** Shares in Schott Pharma 1SXP.DE rise 4.2% in early Frankfurt trade after Barclays upgrades the German pharma packaging supplier to "Overweight" from "Equal Weight"
** Barclays says it expects an earnings inflection after three years of downgrades, helped by renegotiated contracts, improving polymer demand and growth in ready-to-use and speciality vials
** Broker says previous pressures from destocking, vial overcapacity, lower glass pre-filled syringe orders and slower polymer demand are "now largely in the rear-view mirror"
** "Schott is well positioned in an attractive end market, and is one of the few names in EU Medtech where we see upside to earnings", the broker said
** Barclays sees Schott's growth accelerating from 5.8% in FY 2026 to 8.6% in FY 2030, supported by demand for injectable drugs, biologics, biosimilars and GLP-1-related packaging
** Up to the previous session's close, shares were up 43%​ YTD
** Out of 13 analysts that cover SCHOTT Pharma AG & Co. KGaA, 10 rate the stock "strong buy" or "buy," two rate "hold" and one rates the stock "sell" - LSEG data

(Reporting by Basile Day)
((Basile.Day@thomsonreuters.com))